Agios Pharmaceuticals, Inc.

344 articles about Agios Pharmaceuticals, Inc.

• Agios Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed Chief Financial Officer

  9/26/2022

  Agios Pharmaceuticals, Inc. announced the grant of inducement equity awards outside of the Company’s 2013 Stock Incentive Plan to its newly appointed Chief Financial Officer, Cecilia Jones.

• Agios Appoints Cecilia Jones as Chief Financial Officer

  9/19/2022

  Agios Pharmaceuticals, Inc. today announced the appointment of Cecilia Jones to the role of chief financial officer, effective Sept. 26, 2022.

• Agios Receives Positive CHMP Opinion for PYRUKYND® (mitapivat) for the Treatment of Pyruvate Kinase (PK) Deficiency in Adult Patients

  9/16/2022

  Agios Pharmaceuticals, Inc. announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency adopted a positive opinion on September 15, 2022, recommending the granting of a marketing authorization for PYRUKYND® for the treatment of pyruvate kinase deficiency in adult patients.

• Agios to Participate in September Investor Conferences

  8/24/2022

  Agios Pharmaceuticals, Inc. today announced that the company is scheduled to present at the following September investor conferences: Wells Fargo Healthcare Conference on Wednesday, September 7, 2022 at 8:35 a.m. ET; and Morgan Stanley 20th Annual Global Healthcare Conference on Monday, September 12, 2022 at 4:50 p.m.

• Agios Announces Publication of Phase 3 ACTIVATE-T Data in The Lancet Haematology Demonstrating Benefits of PYRUKYND® (mitapivat) for Adults with Pyruvate Kinase Deficiency

  8/18/2022

  Agios Pharmaceuticals, Inc. (NASDAQ: AGIO), today announced that data from the core period of the pivotal Phase 3 ACTIVATE-T study of PYRUKYND® (mitapivat) in adults with pyruvate kinase (PK) deficiency who receive regular transfusions were published on August 18, 2022, in The Lancet Haematology.

• Agios Appoints Rahul Ballal and Cynthia Smith to Board of Directors

  8/15/2022

  Agios Pharmaceuticals, Inc., a leader in the field of cellular metabolism pioneering therapies for genetically defined diseases, announced the appointments of Rahul Ballal, Ph.D., chief executive officer of Imara, and Cynthia Smith, former chief commercial officer of ZS Pharma, to its board of directors.

• Agios Announces Publication of Phase 2 Data in The Lancet Demonstrating Safety and Efficacy of PYRUKYND® (mitapivat) in Non-transfusion-dependent α- and β-Thalassemia

  8/11/2022

  Agios Pharmaceuticals, Inc. (NASDAQ: AGIO), today announced that data from the core period of the open-label, Phase 2 study of PYRUKYND® (mitapivat) in adults with non-transfusion-dependent α- or β-thalassemia were published on August 11, 2022, in The Lancet.

• Agios Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed Chief Executive Officer

  8/8/2022

  Agios Pharmaceuticals, Inc., a leader in the field of cellular metabolism pioneering therapies for genetically defined diseases, announced the grant of inducement equity awards outside of the company’s 2013 Stock Incentive Plan to its newly appointed chief executive officer, Brian Goff.

• Agios Appoints Brian Goff as Chief Executive Officer

  7/12/2022

  Agios Pharmaceuticals, Inc. (NASDAQ: AGIO), a leader in the field of cellular metabolism pioneering therapies for genetically defined diseases, today announced that effective August 8, 2022, Jackie Fouse, Ph.D., will transition to the role of chair of the board of directors and Brian Goff will assume the role of chief executive officer.

• CENTOGENE and Agios Expand Partnership for Clinical Development of PYRUKYND® (mitapivat) to Treat Children With Rare Blood Disease

  6/13/2022

  Centogene N.V. announced that it has expanded its long-standing PYRUKYND® partnership with Agios Pharmaceuticals, Inc., a leader in the field of cellular metabolism pioneering therapies for genetically defined diseases.

• Agios Presents New Clinical Data Supporting the Benefits of PYRUKYND® (mitapivat) Treatment in Adults with PK Deficiency at European Hematology Association Annual Congress

  6/10/2022

  Agios Pharmaceuticals, Inc. (NASDAQ: AGIO), a leader in the field of cellular metabolism pioneering therapies for genetically defined diseases, today reported new data further underscoring the significant burden of disease in adults with pyruvate kinase (PK) deficiency regardless of genotype and supporting the potential benefits of treatment with PYRUKYND® for these patients.

• 

  Agios' Pivot to Late-Stage Projects Results in Loss of 50 Jobs

  5/17/2022

  Agios Pharmaceuticals is cutting its staff numbers by 50 as part of plans to lay low on exploratory research efforts to focus on the success of late-stage initiatives.

• Agios Announces Evolution of Research Organization - May 16, 2022

  5/16/2022

  Agios Pharmaceuticals, Inc., a leader in the field of cellular metabolism pioneering therapies for genetically defined diseases, announced the evolution of its research organization.

• Agios to Present Clinical and Translational Data at the European Hematology Association Annual Congress

  5/12/2022

  Agios Pharmaceuticals, Inc. announced that clinical and translational data will be presented at the European Hematology Association Annual Congress, hosted virtually and in person in Vienna on June 9-12, 2022.

• Agios to Present at the RBC Capital Markets Global Healthcare Conference on May 17, 2022

  5/10/2022

  Agios Pharmaceuticals, Inc. announced that the company is scheduled to present at the RBC Capital Markets Global Healthcare Conference on Tuesday, May 17, 2022, at 10:30 a.m. ET.

• Agios Reports Business Highlights and First Quarter 2022 Financial Results

  5/5/2022

  Agios Pharmaceuticals, Inc. (NASDAQ: AGIO), a leader in the field of cellular metabolism pioneering therapies for genetically defined diseases, today reported business highlights and financial results for the first quarter ended March 31, 2022.

• Agios to Webcast Conference Call of First Quarter 2022 Financial Results on May 5, 2022

  4/21/2022

  Agios Pharmaceuticals, Inc. today announced the company will host a conference call and live webcast on Thursday, May 5, 2022, at 8:00 a.m. ET to report its first quarter 2022 financial results and other business highlights.

• Agios Announces Publication of Phase 3 ACTIVATE Study in New England Journal of Medicine Demonstrating Benefits of PYRUKYND® (mitapivat) for Adults with Pyruvate Kinase Deficiency

  4/14/2022

  Agios Pharmaceuticals, Inc. today announced that data from the core period of the pivotal Phase 3 ACTIVATE study of PYRUKYND.

• Agios to Participate in March 2022 Investor Conferences

  2/28/2022

  Agios Pharmaceuticals, Inc. announced the company is scheduled to present at the following March investor conferences.

• Agios Reports Fourth Quarter and Full Year 2021 Financial Results

  2/24/2022

  Agios Pharmaceuticals, Inc., a leader in the field of cellular metabolism pioneering therapies for genetically defined diseases, reported business highlights and financial results for the fourth quarter and year ended Dec. 31, 2021.